Diisopropylmethylphosphinoxid | 60593-45-5

• 分子结构分类: 有机化合物 - 有机磷化合物 - 有机膦及其衍生物
• 英文名称: Diisopropylmethylphosphinoxid
• 英文别名: 2-[Methyl(propan-2-yl)phosphoryl]propane
• CAS: 60593-45-5
• 化学式: C₇H₁₇OP
• 分子量: 148.185
• InChiKey: FRCNKYKTJBGVAL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  二氯甲基苯 、 Diisopropylmethylphosphinoxid 反应 17.0h， 以75%的产率得到二异丙基次膦酸酐
  参考文献：
  名称：

  Gazizov, M. B.; Kachalova, T. N.; Karimova, R. F., Russian Journal of General Chemistry, 1997, vol. 67, # 12, p. 1942 - 1943

  摘要：

  DOI：
• 作为产物：
  描述：

  diisopropylphosphinous iodide 在 水 、 三乙胺 作用下， 以 乙醚 为溶剂， 生成 Diisopropylmethylphosphinoxid
  参考文献：
  名称：

  Kabachnik,M.M. et al., Journal of general chemistry of the USSR, 1979, vol. 49, p. 1264 - 1269

  摘要：

  DOI：

文献信息

• 2'-AZIDO SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES
  申请人：Girijavallabhan Vinay

  公开号：US20140206640A1

  公开（公告）日：2014-07-24

  The present invention relates to 2′-Azido Substituted Nucleoside Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein B, X, R 1 , R 2 and R 3 are as defined herein. The present invention also relates to compositions comprising at least one 2′-Azido Substituted Nucleoside Derivative, and methods of using the 2′-Azido Substituted Nucleoside Derivatives for treating or preventing HCV infection in a patient.

  本发明涉及式(I)的2'-叠氮基取代核苷衍生物及其药学上可接受的盐，其中B、X、R1、R2和R3如本文所定义。本发明还涉及包含至少一种2'-叠氮基取代核苷衍生物的组合物，以及使用这些2'-叠氮基取代核苷衍生物治疗或预防患者HCV感染的方法。
• 2'-CYANO SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF USEFUL FOR THE TREATMENT OF VIRAL DISEASES
  申请人：Girijavallabhan Vinay

  公开号：US20140161770A1

  公开（公告）日：2014-06-12

  The present invention relates to 2′-Cyano Substituted Nucleoside Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein B, X, R 1 , R 2 and R 3 are as defined herein. The present invention also relates to compositions comprising at least one 2′-Cyano Substituted Nucleoside Derivative, and methods of using the 2′-Cyano Substituted Nucleoside Derivatives for treating or preventing HCV infection in a patient.

  本发明涉及式(I)的2'-氰基取代核苷衍生物及其药学上可接受的盐，其中B、X、R1、R2和R3如本文所定义。本发明还涉及包含至少一种2'-氰基取代核苷衍生物的组合物，以及使用这些2'-氰基取代核苷衍生物治疗或预防患者HCV感染的方法。
• Surfactant-Enabled Transition Metal-Catalyzed Chemistry
  申请人：Berl Volker

  公开号：US20110130562A1

  公开（公告）日：2011-06-02

  In one embodiment, the present application discloses mixtures comprising (a) water in an amount of at least 1% wt/wt of the mixture; (b) a transition metal catalyst; and (c) one or more solubilizing agents; and methods for using such mixtures for performing transition metal mediated bond formation reactions.

  本申请公开了一种组合物，包括(a)至少占组合物总重量1%的水；(b)过渡金属催化剂；以及(c)一种或多种增溶剂；以及使用该组合物进行过渡金属介导的键形成反应的方法。
• Di-isopropyl-phosphinoyl-alkanes as topical agents for the treatment of sensory discomfort
  申请人：Wei Edward T.

  公开号：US20150164924A1

  公开（公告）日：2015-06-18

  The present discovery pertains generally to the field of therapeutic compounds. More specifically the present discovery pertains to certain di-isopropyl-phosphinoyl-alkanes as described herein, DIPA-1-5, DIPA-1-6, DIPA-1-7, DIPA-1-8, and DIPA-1-9, collectively referred to herein as “DIPA compounds”, that are useful, for example, in the treatment of disorders (e.g., diseases) including: sensory discomfort (e.g., caused by irritation, itch, or pain); a skin dysesthesia; dermatitis; ocular pain and discomfort; heat discomfort; heat stress; flushing and/or night sweats (vasomotor symptoms); post-operative hypothermia; post-anaesthetic shivering; fatigue; tiredness; depression; cognitive dysfunction; and to enhance cognitive function. The applicant has found that localized delivery of DIPA compounds to the upper eyelid and/or facial skin has an alerting and enhancement effect on behavior and can be used to give a cosmetic refreshing look, to mental alertness, to reduce fatigue, and to improve work output. The present discovery also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, for example, in therapy, in diagnosis of neuropathic pain, and in study of TRPM8 function.

  本发现通常涉及治疗化合物领域。更具体地，本发现涉及如下所述的某些二异丙基磷酰基烷烃，即DIPA-1-5、DIPA-1-6、DIPA-1-7、DIPA-1-8和DIPA-1-9，以下统称为“DIPA化合物”，这些化合物在治疗包括但不限于感觉不适（例如由刺激、瘙痒或疼痛引起）、皮肤感觉异常、皮炎、眼部疼痛和不适、热感不适、热应激、潮红和/或盗汗（血管运动症状）、术后低体温、麻醉后颤抖、疲劳、疲倦、抑郁、认知功能障碍以及增强认知功能等疾病（例如疾病）的治疗中具有用途。申请人发现将DIPA化合物局部传递至上眼睑和/或面部皮肤对行为具有警觉和增强效果，并可用于给予一种化妆上的焕然一新的外观，提高精神警觉度，减轻疲劳，并提高工作产出。本发现还涉及包含此类化合物的药物组合物，以及此类化合物和组合物的用途，例如在治疗、神经病痛诊断和TRPM8功能研究中的应用。
• LIGHT EMITTING DEVICES AND COMPOSITIONS
  申请人：FROEHLICH JESSE

  公开号：US20120273765A1

  公开（公告）日：2012-11-01

  A light emitting composition includes a light-emitting lumophore-functionalized nanoparticle, such as an organic-inorganic light-emitting lumophore-functionalized nanoparticle. A light emitting device includes an anode, a cathode, and a layer containing such a light-emitting composition. In an embodiment, the light emitting device can emit white light.

  一种发光组合物包括一种发光量子点功能化纳米颗粒，例如有机-无机发光量子点功能化纳米颗粒。一种发光器件包括阳极、阴极和含有这种发光组合物的层。在一个实施例中，这种发光器件可以发出白光。